ImmunoPrecise Antibodies (TSXV: IPA) (NASDAQ: IPA) has officially been approved for listing on the Nasdaq Global Markets. The company announced the news this morning, indicating that it will trade under the same symbol that Canadian shareholders are accustomed to, “IPA”.
Trading of ImmunoPrecise’s shares on the Nasdaq is expected to commence on December 30. The company is also expected to remain listed on the TSX Venture exchange as well, under its current symbol.
The announcement follows the firm filing the application for such listing back in September. At the time, the company indicated that it was motivated for the dual listing as a result of the desire to gain greater exposure to both retail and institutional investors in the United States as well as internationally.
Sponsored · Cambria Gold Mines
ImmunoPrecise Antibodies last traded at $14.76 on the TSX Venture.
Information for this analysis was found via Sedar and ImmunoPrecise Antibodies Ltd. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
